U.S. markets close in 4 hours 15 minutes
  • S&P 500

    4,245.31
    -1.28 (-0.03%)
     
  • Dow 30

    34,277.33
    -22.00 (-0.06%)
     
  • Nasdaq

    14,091.12
    +18.26 (+0.13%)
     
  • Russell 2000

    2,315.44
    -4.63 (-0.20%)
     
  • Crude Oil

    72.90
    +0.78 (+1.08%)
     
  • Gold

    1,860.30
    +3.90 (+0.21%)
     
  • Silver

    27.89
    +0.20 (+0.71%)
     
  • EUR/USD

    1.2117
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.4890
    -0.0100 (-0.67%)
     
  • GBP/USD

    1.4104
    +0.0022 (+0.16%)
     
  • USD/JPY

    109.9250
    -0.1090 (-0.10%)
     
  • BTC-USD

    38,720.58
    -1,217.07 (-3.05%)
     
  • CMC Crypto 200

    959.20
    -33.27 (-3.35%)
     
  • FTSE 100

    7,190.72
    +18.24 (+0.25%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Novavax Down Second Straight Day On Concerns About Delays

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Dhirendra Tripathi

Investing.com – Novavax (NASDAQ:NVAX) extended losses for the second consecutive day, plunging 12% in Tuesday’s trade a day after the vaccine maker said it is pushing back its timetable for seeking regulatory approvals for its Covid-19 shot.

The company said it intended to apply for permissions in the U.S, the U.K. and Europe in the next quarter.

Cumulatively, Novavax share price is now down by more than half of its year’s high of $331.

Market makers are puzzled by the continuing delay at the company’s end at a time when the likes of Pfizer (NYSE:PFE)-BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) have supplied millions of doses in the U.S., and AstraZeneca (NASDAQ:AZN) has done so in Europe and India.

A Washington Post report Monday said the company delayed plans to seek emergency use authorization.

The Gaithersburg-based vaccine developer is yet to supply a single dose even as it has manufacturing agreements with India’s Serum Institute, Japan’s Takeda and South Korea’s SK Bioscience to make the shots.

Related Articles

Novavax Down Second Straight Day On Concerns About Delays

Walgreens Boots Alliance Offers Major Upside

3 Clean Energy Stocks Under $10 to Add to Your Watchlist